South Korea’s Dangerous Dance with Diet Drugs: When Thin Becomes Too Thin
In a nation already celebrated as one of the slimmest in the OECD, South Korea is witnessing a startling surge in the demand for weight-loss medications. But here’s where it gets controversial: this trend isn’t just about health—it’s about an obsession with thinness that’s pushing people to misuse drugs meant for medical conditions. And this is the part most people miss: even as obesity rates creep up, the real crisis might be the societal pressure to be dangerously thin.
By December 2025, South Korea’s health authorities are sounding alarms as the misuse of diet drugs escalates, fueled by rising body-image pressures and easy access to medications. Adding to the complexity, a new wave of oral GLP-1 medications is set to hit the market as early as next year. Eli Lilly’s orforglipron and Novo Nordisk’s oral semaglutide are poised for approval, promising expanded treatment options for obesity and diabetes. Meanwhile, Korean drugmaker Hanmi Pharmaceutical’s efpeglenatide is expected to launch in the second half of 2026, further broadening the landscape.
The Global Context: Obesity on the Rise, But at What Cost?
Globally, obesity is a growing health challenge, with the World Health Organization (WHO) recently issuing its first guidelines recommending GLP-1 therapies as a treatment for obesity as a chronic, relapsing disease. Yet, South Korea’s obesity rate remains one of the lowest in the OECD at 5.7 percent under WHO standards. However, under Korea’s stricter BMI threshold of 25 or above, the story changes. Here, 41.4 percent of men and 23 percent of women are classified as obese—and these numbers are climbing steadily.
Misuse Runs Rampant as Aesthetic Goals Override Medical Need
Despite their intended medical use, anti-obesity drugs like Novo Nordisk’s Wegovy have become go-to solutions for aesthetic weight loss. Introduced in Korea in October 2024, Wegovy has already shown alarming signs of misuse. Shockingly, the Health Insurance Review & Assessment Service reported that as of August 2025, the drug was illegally prescribed to 69 children under 12 and 194 pregnant women—groups explicitly barred from using it. Even more concerning, large numbers of prescriptions were written by specialists unrelated to obesity treatment, including psychiatrists, urologists, and dentists.
Authorities also uncovered 111 cases of illegal advertising in the first half of 2025, many promising access to the drug without proper medical oversight. While men are nearly twice as likely to be obese under Korea’s BMI 25 standard, women accounted for a staggering 71.5 percent of all prescriptions for Wegovy and Saxenda between 2020 and June 2025. Anecdotal evidence suggests that many are using these drugs without medical need, driven by societal pressures to conform to unrealistic beauty standards.
Social Media: The Double-Edged Sword Amplifying the Crisis
Experts argue that Korea’s obsession with thinness has been supercharged by social media. In July 2025, the Korea Health Promotion Institute issued a public advisory against “distorted body ideals” spreading online, specifically calling out the “bony arm” trend—a disturbing glorification of arms so thin that bone outlines are visible. The institute linked this trend to a 39 percent increase in eating-disorder patients between 2020 and 2023. “Trends like the ‘bony arm’ are a direct threat to public health, especially for adolescents and women,” warned institute chief Kim Heon-joo.
A study by professors at Changwon National University and Soongsil University revealed a troubling pattern: young women exposed to pro-anorexia content often progress from longing for thinness to achieving and maintaining it, frequently reinforced by online communities. International research, including Facebook’s internal studies reported by the Wall Street Journal in 2021, highlights how platforms like Instagram exacerbate body-image issues among teenage girls, with some mental health impacts unique to the platform.
The Unseen Risks: When Non-Obese Individuals Turn to Prescription Drugs
Many experts argue that social media ecosystems—filled with dieting vlogs, body transformation videos, and “bone skinny” tutorials—are shaping unrealistic norms of beauty. This is driving non-obese individuals toward prescription drugs, often without understanding the risks. Even as Korea’s obesity rate under local standards rises steadily—reaching 34.4 percent in 2024, up from 26.3 percent in 2015—public understanding of obesity remains limited. A survey by the Korean Society for the Study of Obesity found that only 38 percent of non-medical respondents viewed obesity as a disease, compared to 90 percent of doctors. Many still believe it can be overcome through willpower alone.
Authorities Sound the Alarm: Balancing Access with Accountability
While the increasing number of medically obese patients justifies greater access to treatment, casual or cosmetic use of GLP-1 drugs poses unnecessary risks. In October 2025, the Ministry of Health and Welfare announced plans to designate Wegovy, Saxenda, and other anti-obesity drugs as medications at risk of misuse or abuse. “People with normal BMI who take these medications solely for slimming purposes face heightened risks such as anemia, hair loss, and muscle loss,” cautioned Kang Jae-hun, a family medicine professor at Kangbuk Samsung Hospital.
The Bigger Question: Where Do We Draw the Line?
As South Korea grapples with this dual crisis of rising obesity and dangerous thinness obsession, the question remains: How do we balance the need for effective obesity treatments with the societal pressures driving misuse? Are we doing enough to address the root causes of these distorted body ideals? And what role should social media platforms play in curbing harmful content? The conversation is far from over, and we want to hear from you. Do you think the risks of diet drug misuse outweigh the benefits? Share your thoughts in the comments below.
